Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Intravenous Milk Thistle (Silibinin-Legalon) for Hepatic Failure Induced by Amatoxin/Amanita Mushroom Poisoning

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2017 by Madaus Inc
Sponsor:
Collaborator:
Mylan Inc.
Information provided by (Responsible Party):
Madaus Inc
ClinicalTrials.gov Identifier:
NCT00915681
First received: June 4, 2009
Last updated: April 3, 2017
Last verified: April 2017

June 4, 2009
April 3, 2017
February 2010
December 31, 2018   (Final data collection date for primary outcome measure)
percentage of patients survived without liver transplantation [ Time Frame: 1 month ]
prevention of severe morbidity (liver transplantation) and death [ Time Frame: 1 month ]
Complete list of historical versions of study NCT00915681 on ClinicalTrials.gov Archive Site
Not Provided
  • Improvement in presenting abnormalities as evaluated by time to normality for hepatic and renal function tests (AST, ALT, bilirubin, PT/INR, creatinine). [ Time Frame: 1 month ]
  • cutaneous reactions [ Time Frame: 1 month ]
  • sodium [ Time Frame: 1 month ]
  • hemoglobin [ Time Frame: 1 month ]
Not Provided
Not Provided
 
Intravenous Milk Thistle (Silibinin-Legalon) for Hepatic Failure Induced by Amatoxin/Amanita Mushroom Poisoning
Prevention and Treatment of Amatoxin Induced Hepatic Failure With Intravenous Silibinin ( Legalon® SIL): An Open Multicenter Clinical Trial
Legalon® SIL will be administered to patients with amatoxin poisoning diagnosed by history, gastrointestinal symptoms, elevated liver enzymes, and/or diagnostic assay (should one become available). Patients may or may not also demonstrate abnormalities in bilirubin and/or creatinine. Treatment consists of a 5 mg/kg loading dose followed by 20 mg/kg/day via continuous infusion. The treating physician is expected to administer supportive therapy of his/her choosing but consistent with best practices. Legalon® SIL will be stopped when coagulopathy is no longer present, and when liver function tests have returned significantly towards the normal range. Patients will be followed 7-14 days after the end of Legalon® SIL therapy with follow up lab studies.
Patients with suspected amatoxin poisoning are reviewed for enrollment in the study by contacting the Legalon SIL study hotline (866) 520-4412.
Interventional
Phase 2
Phase 3
Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
  • Amatoxin Poisoning
  • Amanita Poisoning
  • Mushroom Poisoning
  • Liver Failure
Drug: Silibinin
20 mg/kg/day IV
Other Name: Legalon SIL
Experimental: Legalon SIL
Silibinin: loading dose of one hour infusion of 5 mg/kg, followed by 20 mg/kg/day infused continuously via pump
Intervention: Drug: Silibinin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
50
December 31, 2018
December 31, 2018   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • History of eating foraged mushrooms
  • Gastrointestinal symptoms suggestive of amatoxin poisoning (cramping abdominal pain, nausea, vomiting, and / or watery diarrhea) within 48 hrs of mushroom ingestion
  • Liver function tests suggestive of amatoxin poisoning: AST or ALT above the upper limit of normal within 48 hrs after mushroom ingestion
  • Gender: male or female
  • Age: > 2 yr
Sexes Eligible for Study: All
2 Years and older   (Child, Adult, Senior)
No
Contact: Todd Mitchell, MD 831-479-7916 tmitchmd@yahoo.com
Contact: Gail L Tribble, BSN 412-651-9530 gail.tribble@mylan.com
United States
 
 
NCT00915681
SB16A1.07
No
Not Provided
Not Provided
Not Provided
Madaus Inc
Madaus Inc
Mylan Inc.
Principal Investigator: Todd Mitchell, MD Dominican Santa Cruz Hospital
Madaus Inc
April 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP